Research Analysts Set Expectations for SGMO Q3 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Stock analysts at HC Wainwright raised their Q3 2025 earnings estimates for shares of Sangamo Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will post earnings of ($0.08) per share for the quarter, up from their prior estimate of ($0.11). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ FY2025 earnings at ($0.17) EPS, FY2026 earnings at ($0.17) EPS and FY2027 earnings at ($0.04) EPS.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The company had revenue of $6.44 million for the quarter, compared to analysts’ expectations of $7.90 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%.

SGMO has been the subject of a number of other reports. Barclays dropped their price target on Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating for the company in a research note on Wednesday, May 14th. Truist Financial cut their target price on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $2.00 price target on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $4.50.

Sangamo Therapeutics Price Performance

Shares of SGMO opened at $0.50 on Monday. Sangamo Therapeutics has a 1 year low of $0.30 and a 1 year high of $3.18. The company has a 50 day simple moving average of $0.71 and a two-hundred day simple moving average of $1.30. The firm has a market cap of $116.37 million, a P/E ratio of -0.67 and a beta of 1.46.

Hedge Funds Weigh In On Sangamo Therapeutics

Several hedge funds have recently made changes to their positions in SGMO. Golden State Equity Partners boosted its holdings in Sangamo Therapeutics by 2,592.3% in the fourth quarter. Golden State Equity Partners now owns 325,684 shares of the biopharmaceutical company’s stock valued at $332,000 after purchasing an additional 313,587 shares during the last quarter. Sageworth Trust Co acquired a new position in Sangamo Therapeutics in the fourth quarter valued at approximately $61,000. SBI Securities Co. Ltd. purchased a new stake in Sangamo Therapeutics in the 4th quarter worth approximately $28,000. Charles Schwab Investment Management Inc. grew its stake in shares of Sangamo Therapeutics by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,139,252 shares of the biopharmaceutical company’s stock worth $1,162,000 after purchasing an additional 35,926 shares during the period. Finally, E Fund Management Co. Ltd. acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at $25,000. 56.93% of the stock is owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.